

1 **Liver Chemistries in Patients with Severe or Non-severe**
2 **COVID-19: A Meta-Analysis**

3

4 **Short title:** Liver Chemistries in COVID-19

5

6 Xuan Dong^{1,2*}, Dan-Yi Zeng^{2*}, Yan-Yan Cai^{1*}, Wei-Ming Chen², Qing-Qing Xing¹,

7 Yan-Dan Ren³, Mei-Zhu Hong^{4†}, and Jin-Shui Pan^{1,2†}

8

9 ¹Liver Research Center, the First Affiliated Hospital of Fujian Medical University,

10 Fuzhou, Fujian, China;

11 ²School of Medicine, Xiamen University, Xiamen, Fujian, China;

12 ³Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen

13 University, Xiamen, Fujian, China;

14 ⁴Department of Traditional Chinese Medicine, Zhongshan Hospital Affiliated to

15 Xiamen University, Xiamen, Fujian, China

16

17 **E-mails:**

18 Xuan Dong 362485659@qq.com

19 Dan-Yi Zeng 1184359451@qq.com

20 Yan-Yan Cai 474349346@qq.com

21 Wei-Ming Chen 345173327@qq.com

22 Qing-Qing Xing 582398903@qq.com

23 Yan-Dan Ren 916659998@qq.com

24 Mei-Zhu Hong 546777397@qq.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Liver Chemistries in Patients with COVID-19

25 Jin-Shui Pan j.s.pan76@gmail.com

26

27 *These authors contributed equally to this work.

28

29 †**Correspondence:**

30 Jin-Shui Pan, MD, PhD

31 Liver Research Center

32 the First Affiliated Hospital of Fujian Medical University

33 No. 20 Chazhong Road,

34 Fuzhou 350001, Fujian, China.

35 E-mail: j.s.pan76@gmail.com

36

37 Mei-Zhu Hong, MD

38 Department of Traditional Chinese Medicine

39 Zhongshan Hospital Affiliated to Xiamen University

40 201 Hu-Bin Nan Road

41 Xiamen, Fujian 361004, China

42 E-mail: 546777397@qq.com

43 Tel: +86-592-229-2015

44

45 **Word count:** 2555

46 **Word count of abstract:** 239

47 **Number of tables:** 1; **Number of figures:** 5

48 **Number of supplementary figures:** 5

49 **ABSTRACT**

50 **Background and Aims:** Cumulating observations have indicated that patients with
51 coronavirus disease (COVID-19) undergo different patterns of liver impairment. We
52 performed a meta-analysis of published liver manifestations and described the liver
53 damage in COVID-19.

54 **Methods:** We searched PubMed, Google Scholar, Embase, Cochrane Library,
55 medRxiv, bioRxiv, and three Chinese electronic databases through April 18, 2020, in
56 accordance with the Preferred Reporting Items for Meta-Analyses. We analyzed
57 pooled data on liver chemistries stratified by COVID-19 severity using a fixed or
58 random-effects model.

59 **Results:** In the meta-analysis of 37 studies, which included a total of 6,235 patients,
60 the pooled mean alanine aminotransferase (ALT) was 36.4 IU/L in the severe
61 COVID-19 cases and 27.8 IU/L in the non-severe cases (95% confidence interval [CI]:
62 -9.4 to -5.1 , $p < 0.0001$). The pooled mean aspartate aminotransferase (AST) was
63 46.8 IU/L in the severe cases and 30.4 IU/L in the non-severe cases (95% CI: -15.1 to
64 -10.4 , $p < 0.0001$). Furthermore, regardless of disease severity, the AST level is often
65 higher than the ALT level. Compared with the non-severe cases, the severe cases
66 tended to have higher γ -glutamyltransferase levels but lower albumin levels.

67 **Conclusions:** In this meta-analysis, we comprehensively described three patterns of
68 liver impairment related to COVID-19, namely hepatocellular injury, cholestasis, and
69 hepatocellular dysfunction, according to COVID-19 severity. Patients with abnormal
70 liver test results are at higher risk of progression to severe disease. Close monitoring
71 of liver chemistries provides an early warning against disease progression.

72

73 **KEYWORDS:** PRISMA, COVID-19, SARS-CoV-2, Meta-analysis

74 **Lay Summary**

75 Data on abnormal liver chemistries related to coronavirus disease (COVID-19) are
76 cumulating but are potentially confusing. We performed a meta-analysis of 37 studies
77 that included a total of 6,235 patients with COVID-19. We noted that patients with
78 abnormal liver test results are at higher risk of progression to severe disease and close
79 monitoring of liver chemistries provides early warning against disease progression.

80

81 **INTRODUCTION**

82 According to the situation report released by the World Health Organization (WHO),
83 as of April 18, 2020, 2,160,207 coronavirus disease (COVID-19) cases were
84 confirmed globally, of which 146,088 led to deaths [1]. Although effectively
85 controlled in mainland China, the spread and upward trend of COVID-19 have
86 accelerated dramatically worldwide. In response to the emerging threat posed by
87 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
88 2), the WHO has declared a Public Health Emergency of International Concern on
89 January 30, 2020, which was further labeled as a pandemic on March 11, 2020.
90 Similarly, the other two previously identified coronaviruses, namely SARS-CoV and
91 Middle East Respiratory Syndrome-CoV, SARS-CoV-2 causes severe viral
92 pneumonia in humans. As no specific acquired immunity exists in the general
93 population, SARS-CoV-2 has high infectivity, which has resulted in an ongoing
94 global health crisis.

95 Apart from the respiratory system, the urinary system, gastrointestinal tract, and even
96 the central nervous system are the probable target organs of SARS-CoV-2, which
97 utilizes the angiotensin-converting enzyme 2 (ACE2) receptors of the respiratory and
98 gastrointestinal tracts as the entry point for epithelial cells [2]. Among patients'
99 common complaints related to COVID-19 are gastrointestinal symptoms, including
100 nausea/vomiting, diarrhea, and abdominal pain [3-6]. Abundant ACE2 protein
101 expression in the glandular cells of gastric, duodenal, and rectal epithelia supports the
102 entry of SARS-CoV-2 into the host epithelial cells [7]. Single-cell RNA sequencing
103 has revealed a specific ACE2 expression in cholangiocytes [8]. Thus, performing liver
104 chemistry tests for a number of patients with COVID-19 seems reasonable. In fact,
105 several studies have found liver injury in patients with COVID-19 [9-13].

Liver Chemistries in Patients with COVID-19

106 Furthermore, cumulating observations have indicated that different patterns of
107 abnormal liver chemistries exist between patients with severe and non-severe
108 COVID-19. Although liver manifestations of COVID-19 pose an important diagnostic
109 challenge to clinicians when treating patients with symptoms related to COVID-19 on
110 initial presentation, these are potentially useful for recognizing severe cases of
111 COVID-19 in the early stage.

112 Considering the diverse clinical manifestations and increasing number of reported
113 COVID-19 cases, a systematic summary of the liver manifestations of COVID-19 is
114 urgently needed.

115 Liver chemistries generally consist of hepatocellular injury-related indexes, including
116 alanine aminotransferase (ALT) and aspartate aminotransferase (AST); cholestatic
117 injury-related indexes, comprised of alkaline phosphatase (AKP) and γ -
118 glutamyltransferase (GGT); and hepatocellular function-related indexes such as
119 albumin (ALB) level and prothrombin time (PT)^[14]. In general, total bilirubin (TBIL),
120 direct bilirubin (DBIL), and globulin (GLB) levels, and international standardized
121 ratio (INR) are also assessed in clinical practice. However, observations to
122 comprehensively analyze liver chemistries in patients with COVID-19 patients are
123 rather few. Hence, the aim of this study was to provide a comprehensive view of liver
124 test parameters in patients with severe and non-severe COVID-19. With better
125 knowledge, more targeted therapies and holistic care approaches could be developed.

126

127 **METHODS**

128 **Studies selection**

129 The following databases were searched from December 1, 2019, through April 18,
130 2020: PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and
131 three Chinese electronic databases (CQVIP, Wanfang Data, and Chinese National
132 Knowledge Infrastructure). “Coronavirus,” “COVID-19,” “2019-nCoV-2,” “SARS-
133 CoV-2,” or novel coronavirus were used as search keywords. Potential studies were
134 retrieved in accordance with the PRISMA guideline [15]. Details of the database
135 search are listed in the Supplementary file. The retrieved articles were imported to
136 Endnote X9.3 (Thompson and Reuters, Philadelphia, Pennsylvania), and duplicates
137 were removed.

138 **Selection criteria**

139 The eligibility of the potential studies was determined independently by two authors
140 (XD and WMC), and dissonance was arbitrated by the third author (JSP). The
141 inclusion criteria were as follows: (1) study population: adult COVID-19 patients; (2)
142 study design: case series, case report, prospective cohort study, retrospective cohort
143 study, case-control study, and randomized controlled trial; and (3) language: studies
144 published in English or Chinese. The exclusion criteria were as follows: (1) pediatric
145 patients or pregnant women; (2) patients without nucleic acid data or serology
146 evidence of SARS-CoV2 infection; (3) asymptomatic patients with SARS-CoV2
147 infection; (3) study design: review article, meta-analysis, editorial, or commentary.
148 Studies that only reported the percentages of the indexes related to liver chemistries
149 rather than the mean or median values of the corresponding indexes were also
150 excluded.

151 **Data extraction**

152 For the eligible articles, we recorded the following items: first author, study location,
153 sample size, patient age and sex, and liver chemistry-related indexes such as ALT,
154 AST, TBIL, DBIL, GGT, AKP, and ALB levels. The severity of COVID-19 was also
155 recorded.

156 **Data analysis**

157 The statistical analyses were performed using the R version 3.2.3 statistical software
158 (R Foundation for Statistical Computing). The continuous variables that showed a
159 normal distribution were expressed as mean \pm SD, while those that conformed to a
160 skewed distribution were expressed as median (interquartile range [IQR]). For the
161 studies that provided summary data of median, minimum, and maximum values, we
162 used the method developed by Luo et al [16] to estimate the sample mean and SD for
163 the continuous outcomes. The online tool used is provided at
164 <http://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html>. The 95% confidence
165 interval (CI) was presented as a Forest plot. The Cochran Q test was used to detect the
166 heterogeneity among studies, with a p value of <0.10 indicating significant
167 heterogeneity. The I^2 statistics was calculated to measure the proportion of total
168 variation among the studies to which the heterogeneity was attributed. I^2 values of
169 $<25\%$, $25\text{--}75\%$, and $>75\%$ represent low, moderate, and high heterogeneity,
170 respectively [17]. Publication bias was evaluated using a funnel plot. A subgroup
171 analysis was performed according to disease severity.

172

173 **RESULTS**

174 **Characteristics of the studies included in the meta-analysis**

175 The selection process of the potential studies is depicted in Figure 1. Of the 2,127
176 studies identified, 37 studies were included in the meta-analysis. The characteristics
177 of the enrolled studies are listed in Table 1 [9, 12, 13, 18-51]. Information, including
178 the study location, sample size, patient age and sex, disease severity, INR, PT, and
179 TBIL, DBIL, ALT, AST, GGT, AKP, ALB, and GLB levels, was recorded. The mean
180 ages of patients with non-severe and severe COVID-19 were 51.1 and 64.0 years,
181 respectively (Supplementary Figure 1). In the enrolled studies, male patients
182 accounted for 54.6%. Among the studies that reported disease severity, severe disease
183 accounted for 30.3% (range, 8.0–54.8%) of the cases.

184 **Hepatocellular injury-related abnormalities in liver chemistries**

185 Of the enrolled studies, 37 reported assays of ALT or AST in a total of 6,235 patients
186 with COVID-19. All but one of these studies were from China. Of the 36 enrolled
187 studies from China, 16 (44.4%) were from Hubei Province, where Wuhan is located.
188 The pooled mean ALT level was 36.4 IU/L in the patients with severe COVID-19 and
189 27.8 IU/L in the patients with non-severe COVID-19 (95% CI: -9.4 to -5.1, $p <$
190 0.0001; Figure 2A), with significant heterogeneity among the studies ($I^2 = 69%$, $p <$
191 0.01). Similarly, the pooled mean AST level was 46.8 IU/L in the severe cases and
192 30.4 IU/L in the non-severe cases (95% CI: -15.1 to -10.4, $p < 0.0001$; Figure 2B).
193 Significant heterogeneity was observed for the AST levels among the studies ($I^2 =$
194 68%, $p < 0.01$), which was slightly lower than that of the ALT levels ($I^2 = 69%$, $p <$
195 0.01). Potential publication bias was evaluated using a funnel plot (Supplementary
196 Figure 2). In the patients with COVID-19, the mean AST level tended to be higher

197 than the mean ALT level in both the severe and non-severe groups. Moreover, the gap
198 between the AST and ALT levels (46.8 and 36.5 IU/L, respectively) was even more
199 significant in the severe group (Figure 3). The evaluation of the publication bias is
200 presented in Supplementary Figure 3.

201 **Cholestasis-related abnormalities in liver chemistries**

202 Compared with the studies that reported ALT and AST levels, rather fewer studies
203 focused on cholestasis-related indexes such as AKP, GGT, and DBIL levels. Of the
204 enrolled studies for the meta-analysis, 8 reported AKP assays and 5 studies reported
205 GGT measurements. The pooled mean AKP level was 66.2 IU/L in the patients with
206 severe COVID-19 and 61.0 IU/L in those with non-severe COVID-19 (95% CI: -11.2
207 to 0.1, $p > 0.05$; Figure 4A). The pooled mean GGT level was 43.2 IU/L in the severe
208 group and 30.7 IU/L in the non-severe group (Figure 4B). The pooled mean TBIL
209 level in the severe group was slightly higher than that in the non-severe group.
210 However, the mean TBIL levels in both groups remained within the normal range
211 (Figure 4C). Even fewer studies reported DBIL values in patients with COVID-19. In
212 fact, no significant difference in mean DBIL level was found between the 2 groups
213 (Figure 4D). For the TBIL levels, low heterogeneity was observed among the studies
214 ($I^2 = 14\%$, $p = 0.26$). A funnel plot for the TBIL levels is shown in Supplementary
215 Figure 4.

216 **Hepatocellular function-related abnormalities in liver** 217 **chemistries**

218 Sixteen studies compared the mean ALB levels according to COVID-19 severity,
219 between 713 and 1,772 severe and non-severe cases, respectively (Figure 5A). A
220 significant heterogeneity was observed among the studies ($I^2 = 61\%$, $p < 0.01$). The
221 mean ALB level in the patients with severe disease was significantly lower than that

Liver Chemistries in Patients with COVID-19

222 in the patients with non-severe disease. No significant difference in GLB level was
223 found between the groups ($p = 0.17$; Figure 5B). However, in the coagulation-related
224 indexes such as PT and INR, no significant differences were found between the
225 severity groups. The patients in the severe group tended to have longer PT or higher
226 INR (Figure 5C, 5D). An evaluation of publication bias in relation to ALB level and
227 PT is shown in Supplementary Figure 5.

228

229 **DISCUSSION**

230 In this meta-analysis, 37 studies that consisted a total of 6,235 patients with COVID-
231 19 from China and the United States were enrolled. According to the pooled analysis,
232 three patterns of liver impairment, namely hepatocellular injury, cholestasis, and
233 hepatocellular dysfunction, can develop in a proportion of patients with COVID-19 at
234 variable severity. In brief, the patients with severe COVID-19 tended to have higher
235 ALT/AST, AKP/GGT, and TBIL levels; higher INR; and prolonged PT. However, the
236 severe cases had lower ALB levels than the non-severe cases. The patients with
237 COVID-19 often had higher AST levels than ALT levels, especially in severe cases.
238 We also observed a tendency of the severe cases to arise in the elderly.

239 Although the liver may act as the latent target of SARS-CoV-2, the actual prevalence
240 of abnormal liver chemistries could be underestimated because many studies did not
241 report cholestasis-related indexes such as AKP and GGT levels, and synthetic
242 function-related indexes such as ALB level and INR. Moreover, most studies reported
243 ALT/AST levels on the day of admission but not throughout the disease course. This
244 issue further compromises the role of liver chemistries in disease monitoring and
245 provides an early warning against severe cases. As SARS-CoV-2 can lead to bile duct
246 damage by conquering the ACE2 expressed on cholangiocytes and induce a
247 subsequent cholestatic liver injury [8], cholestasis-related abnormalities could be
248 overlooked.

249 Cumulating studies have linked abnormal liver chemistries to the severity of COVID-
250 19 [9, 19, 25]. Patients with abnormal liver test results are at higher risk of
251 progression to severe disease [9]. In fact, coronavirus infection can cause direct
252 damage to liver cells [11]. Moreover, several underlying diseases, comorbidities, and
253 complications that develop in the course of the disease, such as sepsis and multiple-

Liver Chemistries in Patients with COVID-19

254 organ failure, and drugs that can cause potential liver damage also increase the risk of
255 liver injury. Lopinavir/ritonavir use during hospitalization has been reported to
256 possible lead to liver damage [9, 52]. The liver chemistry tests in the enrolled studies
257 were all performed on admission, which suggests that the influences of the drugs on
258 the liver tests, if any, should be minor.

259 ALB level and PT are known to reflect hepatocellular function. Albumin, which has a
260 circulating half-life of 3 weeks, is a plasma protein exclusively synthesized by the
261 liver [53]. Hypoalbuminemia results from and reflects the inflammatory state, which
262 leads to inflammatory exudate. Effective nutrition support helps to correct
263 hypoalbuminemia [54]. Our meta-analysis revealed that ALB level was lower in the
264 severe cases than in the non-severe cases, which indicated that the severe cases tended
265 to have more intense inflammation and require more solid nutrition support. PT is a
266 far more sensitive measure of hepatocellular function than ALB level because PT may
267 be prolonged in patients with severe liver disease duration of <24 h [14]. In
268 accordance with the alteration of the ALB level, PT was prolonged in the severe cases,
269 which further indicated impairment of hepatocellular function in the severe cases [53].

270 According to our meta-analysis, another interesting feature of liver impairment related
271 to COVID-19 is that the AST level often overrides the ALT level, especially in severe
272 cases. By contrast, in patients with chronic hepatitis B or nonalcoholic fatty liver
273 disease, the ALT level is generally higher than the AST level. Although ALT is
274 present primarily in the liver and is a more specific marker of hepatocellular injury,
275 the distribution of AST is far wider than that of ALT, including the cardiac muscle,
276 skeletal muscle, kidney, and brain [14]. An elevated AST level accompanied by a
277 normal ALT level often suggests cardiac or muscle disease. In fact, cardiac injury is
278 frequent in severe cases of COVID-19, especially in deceased patients [25, 55].

Liver Chemistries in Patients with COVID-19

279 This study has some substantial merits. First, this meta-analysis comprehensively
280 summarized the rapidly evolving and sometimes confusing literature on COVID-19
281 regarding the manifestation of liver chemistries. The extensive coverage of 37 studies
282 allowed a more precise evaluation of the abnormalities of liver chemistries. Our
283 subgroup analysis revealed that the abnormal liver chemistries were associated with a
284 more severe disease course, highlighting the importance of a more extensive
285 monitoring of liver chemistries for both diagnostic and prognostic purposes.
286 Second, this analysis extensively covered all three patterns of liver impairment,
287 namely hepatocellular injury, cholestasis, and hepatocellular dysfunction. Most
288 observations focused on ALT, AST, and ALB levels. However, cholestasis-related
289 impairment (e.g., abnormal AKP and GGT levels) tended to be inadvertently ignored.
290 Moreover, we also compared hepatocellular dysfunction between the severe and non-
291 severe cases. The alarmingly high prevalence of hypoalbuminemia in the severe cases
292 prompts further nutrition support in severe cases. In addition, coagulation dysfunction
293 in severe cases requires vigilance. Third, the enrolled studies included multiple
294 observations not only from mainland China but also from other ethnic groups. This
295 facilitates the assessment of abnormal liver chemistries related to COVID-19 in a
296 broader ethnic context. Fourth, eligible studies preprinted in medRxiv and bioRxiv
297 were also covered, which ensured that our analysis has a clear leading position.
298 However, our study has a few limitations. As mentioned earlier, cholestasis-related
299 indexes such as AKP/GGT level may be under-reported in quite a number of studies,
300 which may lead to less precise pooled data. Second, most studies came from mainland
301 China, which precluded a more precise estimate of the abnormalities of liver
302 chemistries in the other ethnic groups. Most of the studies that came from mainland
303 China seem to have an adverse impact. On the contrary, this helps to abate the

Liver Chemistries in Patients with COVID-19

304 heterogeneity caused by the disease grouping, as some potential discrepancies may
305 exist in the definition of severe and non-severe cases of COVID-19 between different
306 countries.

307

308 **CONCLUSION**

309 In this meta-analysis, we comprehensively described three patterns of liver
310 impairment related to COVID-19, namely hepatocellular injury, cholestasis, and
311 hepatocellular dysfunction, according to COVID-19 severity. Patients with abnormal
312 liver test results are at higher risk of progression to severe disease. Close monitoring
313 of liver chemistries provides an early warning against disease progression.

314

315 **Acknowledgments**

316 **Financial support:** This work was supported by the National Natural Science
317 Foundation of China No. 81871645 (JSP). The funding source did not have any role
318 in the design and conduct of the study; collection, management, analysis, and
319 interpretation of the data; preparation, review, or approval of the manuscript; and
320 decision to submit the manuscript for publication.

321 **Guarantor of the article:** Professor Jin-Shui Pan

322 **Specific author contributions:** JSP and MZH were involved with the study
323 conceptualization and design; analysis and interpretation of data; drafting of the
324 manuscript; and approval of the final version of the manuscript; XD, DYZ, YYC,
325 WMC, QQX, and YDR were involved in data retrieval.

326 **Potential competing interests:** None.

Table 1. Characteristics of the enrolled studies for meta-analysis

Study	Location	Number	Age [(mean±SD, or median (IQR)]	Male, number (%)	Severe, (%)	number	TBIL [(mean±SD, or median (IQR)]	DBIL [(mean±SD, or median (IQR)]	ALT [(mean±SD, or median (IQR)]	AST [(mean±SD, or median (IQR)]
Cao M ^[1]	Shanghai	198	50.1 (16.3)	101 (51.0)	19 (9.7)		8.1 (6.5–10.6)	NA	23.0 (15.0–33.0)	26.0 (20.0–34.0)
Cao W ^[2]	Hubei	128	NA	60 (46.9)	21 (16.4)		NA	NA	31.3±20.4	31.3±20.4
Chen G ^[3]	Hubei	21	56.3 (14.3)	17 (81.0)	11 (52.4)		9.8±5.6	NA	30.0±16.5	38.2±24.6
Han Y ^[4]	Hubei	47	64.9 (31.0–87.0)	26 (55.3)	24 (51.1)		15.8±10.5	NA	27.0 (17.3–49.0)	39.5±23.5
Huang C ^[5]	Hubei	41	49.0 (41.0–58.0)	30 (73.0)	13 (31.7)		11.7 (9.5–13.9)	NA	32.0 (21.0–50.0)	34.0 (26.0–48.0)
Chen X ^[6]	Hunan	291	46.0 (34.0–59.0)	145 (49.8)	50 (17.2)		10.8 (8.2–16.1)	NA	20.7 (14.9–28.9)	24.7 (19.9–31.4)
Fu L ^[7]	Anhui	350	NA	187 (53.5)	139 (39.7)		11.5±5.6	3.8±2.0	26.6±20.5	33.3±21.8
Liu L ^[8]	Chongqing	51	45.0 (34.0–51.0)	32 (62.7)	7 (13.7)		NA	NA	18.0 (14.0–30.0)	21.0 (16.0–30.0)
Wang D ^[9]	Hubei	138	56.0 (42.0–68.0)	75 (54.3)	36 (26.1)		9.8 (8.4–14.1)	NA	24.0 (16.0–40.0)	31 (24.0–51.0)
Wang Y ^[10]	Hubei	110	NA	48 (43.6)	38 (34.5)		NA	NA	NA	NA
Xie H ^[11]	Fujian	79	60.0 (48.0–66.0)	44 (55.7)	28 (35.4)		13.6 (8.8–17.6)	NA	34.0 (18.0–67.0)	30.0 (23.0–50.0)
Xu Y ^[12]	Shanghai	69	57.0 (43.0–69.0)	35 (50.7)	25 (36.2)		NA	NA	19.2 (15.1–33.1)	33.8 (26.1–47.8)

Zhao W ^[13]	Beijing	77	52.0±20.0	34 (44.2)	20 (26.0)	NA	NA	28.0 (20.0–46.0)	29.0 (21.0–42.0)
Zhang Y ^[14]	Hubei	115	49.5±17.1	49 (42.6)	31 (27.0)	11.3±5.2	NA	25.7±21.1	28.3±15.7
Zhang H ^[15]	Chongqing	43	NA	22 (51.2)	14 (32.6)	NA	NA	NA	NA
Zhang G ^[16]	Hubei	221	55.0 (39.0–66.5)	108 (48.9)	55 (24.9)	10.0 (8.0–14.2)	NA	23.0 (16.0–39.0)	29.0 (22.0–49.0)
Qu R ^[17]	Guangdong	30	50.5 (36–65)	16 (53.3)	3 (10.0)	NA	NA	NA	NA
Wu C ^[18]	Hubei	201	51.0 (43.0–60.0)	128 (63.7)	84 (41.8)	11.5 (9.0–14.8)	NA	31.0 (19.8–47.0)	33.0 (26.0–45.0)
Zheng F ^[19]	Hunan	161	45 (33.5–57.0)	80 (49.7)	30 (18.6)	10.9 (8.4–15.4)	NA	20.3 (15.0–24.5)	25.1 (19.9–32.8)
Wan S ^[20]	Chongqing	135	47 (36–55)	72 (53.3)	40 (29.6)	8.6 (5.9–13.7)	NA	26.0 (12.9–33.2)	33.4 (27.8–43.7)
Gao Y ^[21]	Anhui	43	NA	26 (60.5)	15 (34.9)	NA	NA	NA	NA
Xiang TX ^[22]	Jiangxi	49	42.9 (18–78)	33 (67.3)	9 (18.4)	8.2±3.8	2.8±1.4	22.7±12.4	27.4±12.3
Li D ^[23]	Hunan	80	47.8±19.5	40 (50.0)	17 (21.3)	NA	NA	30.0±15.6	36.2±15.4
Lu ZL ^[24]	Hubei	101	NA	34 (33.7)	34 (33.7)	NA	NA	NA	NA
Liu J ^[25]	Hubei	40	48.7±13.9	15 (37.5)	13 (32.5)	10.3±5.0	NA	22.5 (16.8–31.2)	34.1±17.7
Xiong J ^[26]	Hubei	89	53.0±16.9	41 (46.1)	31 (34.8)	NA	NA	NA	NA
Cai Q ^[27]	Guangdong	417	47.0 (34.0–60.0)	198 (47.5)	111 (26.7)	NA	NA	NA	NA
Lei S ^[28]	Hubei	34	55.0 (43.0–63.0)	14 (41.2)	15 (44.1)	9.9 (7.3–16.8)	NA	21.5 (13.0–46.3)	26.0 (20.3–55.7)

Ma J ^[29]	Hubei	37	62.0 (59.0–70.0)	20 (54.1)	20 (54.1)	NA	NA	27.0 (17.0–47.0)	24.0 (20.0–41.0)
Qian Z ^[30]	Shanghai	324	51.0 (36.0–64.0)	167 (51.5)	26 (8.0)	9.5±4.6	NA	27.9±20.0	29.3±21.0
Liu C ^[31]	Gansu	32	38.5 (26.3–45.8)	20 (62.5)	4 (12.5)	16.4 (11.3–21.1)	NA	27.0 (16.9–46.1)	24.7 (18.7–31.8)
Lu H ^[32]	Shanghai	265	NA	NA	22 (8.3)	7.9 (6.5-10.5)		23.0 (15.0-33.0)	24.0 (19.0-33.0)
Mo P ^[33]	Hubei	155	54.0 (42.0-66.0)	86 (55.5)	85 (54.8)	NA	NA	23.0 (16.0-38.0)	32.0 (24.0-48.0)
Zheng Y ^[34]	Zhejiang	34	66.0 (58.0-76.0)	23 (67.6)	15 (44.1)	12.0 (7.6-18.6)	NA	20.0 (20.0-30.0)	NA
Wang Q ^[35]	Beijing	105	45.0 (33.5-59.5)	56 (53.3)	26 (24.8)	10.2 (7.4-12.9)	NA	23.5 (14.0-36.0)	24.2 (19.7-34.8)
Shang H ^[36]	Hubei	514	54.0 (48.0-68.0)	271 (52.7)	162 (31.5)	10.8 (8.1-14.3)	3.6 (2.6-4.9)	34.0 (22.0-55.0)	33.0 (23.0-47.0)
Petrilli CM ^[37]	New York	1582	61.8±17.9	1002 (63.3)	650 (41.1)	NA	NA	36.3±22.0	47.3±26.8

Characteristics of the enrolled studies for meta-analysis (continued)

Study	Location	Number	GGT [(mean±SD, AKP or median (IQR)]	[(mean±SD, or median (IQR)]	ALB [(mean±SD, or median (IQR)]	GLB [(mean±SD, or median (IQR)]	PT [(mean±SD, or median (IQR)]	INR [(mean±SD, or median (IQR)]
Cao M ^[1]	Shanghai	198	NA	NA	40.9 (38.0–43.1)	NA	13.3 (12.9–13.8)	NA
Cao W ^[2]	Hubei	128	NA	NA	NA	NA	NA	NA
Chen G ^[3]	Hubei	21	NA	NA	34.4±5.7	NA	13.8±1.0	NA
Han Y ^[4]	Hubei	47	NA	NA	NA	NA	12.3±1.1	NA


Huang C ^[5]	Hubei	41	NA	NA	31.4 (28.9–36.0)	NA	11.1 (10.1–12.4)	NA
Chen X ^[6]	Hunan	291	NA	NA	37.3 (34.7–40.3)	26.9 (23.8–29.6)	NA	NA
Fu L ^[7]	Anhui	350	32.2±29.2	64.9±21.8	38.7±5.5	28.6±5.4	NA	NA
Liu L ^[8]	Chongqing	51	NA	NA	40.0 (36.0–43.0)	NA	NA	NA
Wang D ^[9]	Hubei	138	NA	NA	NA	NA	13.0±1.0	NA
Wang Y ^[10]	Hubei	110	NA	NA	NA	NA	NA	NA
Xie H ^[11]	Fujian	79	31.5 (19.0–81.3)	79.0 (59.0–100.0)	NA	NA	NA	NA
Xu Y ^[12]	Shanghai	69	NA	NA	NA	NA	12.1 (11.0–13.2)	NA
Zhao W ^[13]	Beijing	77	NA	NA	NA	NA	12.7 (12.2–13.1)	NA
Zhang Y ^[14]	Hubei	115	36.1±45.0	73.7±24.4	38.8±4.4	29.2±4.0	NA	1.2±0.1
Zhang H ^[15]	Chongqing	43	NA	NA	NA	NA	NA	NA
Zhang G ^[16]	Hubei	221	NA	NA	NA	NA	12.9(12.1–13.6)	NA
Qu R ^[17]	Guangdong	30	NA	NA	NA	NA	NA	NA
Wu CM ^[18]	Hubei	201	NA	NA	32.8 (29.1–35.4)	30.7 (28.6–33.7)	11.1 (10.2–11.9)	NA
Zheng F ^[19]	Hunan	161	NA	NA	NA	NA	NA	NA

Wan S ^[20]	Chongqing	135	NA	NA	40.5 (37.0–43.4)	NA	10.9 (10.5–11.4)	NA
Gao Y ^[21]	Anhui	43	NA	NA	NA	NA	NA	NA
Xiang TX ^[22]	Jiangxi	49	NA	65.2±22.9	42.9±5.1	27.7±4.6	12.8±1.5	1.1±0.1
Li D ^[23]	Hunan	80	NA	NA	37.9±3.5	NA	13.9±1.2	NA
Lu ZL ^[24]	Hubei	101	NA	NA	NA	NA	NA	NA
Liu J ^[25]	Hubei	40	NA	NA	NA	NA	13.2±0.6	1.0±0.1
Xiong J ^[26]	Hubei	89	NA	NA	NA	NA	NA	NA
Cai Q ^[27]	Guangdong	417	NA	NA	NA	NA	NA	NA
Lei S ^[28]	Hubei	34	NA	NA	NA	NA	11.5 (10.6–12.4)	NA
Ma J ^[29]	Hubei	37	NA	NA	NA	NA	NA	NA
Qian Z ^[30]	Shanghai	324	39.0±54.4	59.9±19.0	40.6±4.1	NA	NA	1.0±0.1
Liu C ^[31]	Gansu	32	NA	NA	39.0 (36.2–44.2)	NA	NA	NA
Lu H ^[32]	Shanghai	265	NA	NA	40.8 (37.8–43.0)	NA	NA	NA
Mo P ^[33]	Hubei	155	NA	NA	38.0 (34.0–41.0)	28.0 (26.0–31.0)	NA	NA

Zheng Y ^[34]	Zhejiang	34	NA	NA	NA	NA	NA	NA
Wang Q ^[35]	Beijing	105	NA	NA	41.6 (37.9-44.7)	NA	NA	NA
Shang H ^[36]	Hubei	514	31.0 (20.0-56.0)	54.0 (43.0-71.0)	30.1 (26.8-33.9)	31.6 (28.6-35.2)	NA	NA
Petrilli CM ^[37]	New York	1582	NA	NA	NA	NA	NA	NA

327 Abbreviations: SD, standard deviation; IQR, interquartile range; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate
 328 aminotransferase; GGT, γ -Glutamyltransferase; AKP, alkaline phosphatase; ALB, albumin; GLB, globulin; PT, prothrombin time; INR, international
 329 standardized ratio; NA, not available

330 **FIGURE LEGENDS**



331



332 Figure 1. Study selection flow diagram

333 If all the liver chemistry indexes were not reported, these were regarded as “not
334 available” and excluded from the meta-analysis. However, this study still enrolled
335 studies that reported individual liver chemistry indexes if the severity of COVID-19
336 was reported in relation with the index.

337



338

Liver Chemistries in Patients with COVID-19



339
 340 Figure 2. Forest plot of the association between serum ALT/AST level and disease
 341 severity.
 342 Pooled levels of (A) ALT and (B) AST in the patients with COVID-19.
 343 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Liver Chemistries in Patients with COVID-19



344
 345 Figure 3. Forest plot for the comparison of ALT and AST levels in the patients with
 346 COVID-19 stratified by disease severity
 347 A, Forest plot for the comparison of ALT and AST levels in the non-severe cases of
 348 COVID-19. B, Forest plot for the comparison of ALT and AST levels in the severe

Liver Chemistries in Patients with COVID-19


349 cases of COVID-19.

350 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

351

352

Liver Chemistries in Patients with COVID-19



353

354 Figure 4. Forest plot for the association of the cholestasis-related indexes and disease
355 severity.

356 Pooled levels of (A) AKP, (B) GGT, (C) TBIL, and (D) DBIL in the patients with

357 COVID-19.

Liver Chemistries in Patients with COVID-19


358 Abbreviations: AKP, alkaline phosphatase; GGT, γ -Glutamyltransferase; TBIL, total

359 bilirubin; DBIL, direct bilirubin.

360

361

Liver Chemistries in Patients with COVID-19



362
 363 Figure 5. Forest plot for the association of the synthetic function-related indexes and
 364 disease severity
 365 Pooled (A) ALB levels, (B) GLB levels, (C) PTs, and (D) INRs in the patients with
 366 COVID-19.

Liver Chemistries in Patients with COVID-19

367 Abbreviations: ALB, albumin; GLB, globulin; PT, prothrombin time; INR,

368 international standardized ratio.

369

370 **REFERENCES**

- 371 [1] World Health Organization. Coronavirus disease 2019 (COVID-19) Situation
372 Report–89. World Health Organization; 19 April 2020.
- 373 [2] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel
374 Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of
375 SARS Coronavirus. *J Virol* 2020;94.
- 376 [3] Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R, et al. Gastrointestinal
377 Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the
378 Hong Kong Cohort and Systematic Review and Meta-analysis. *Gastroenterology*
379 2020.
- 380 [4] Cholankeril G, Podboy A, Aivaliotis VI, Tarlow B, Pham EA, Spencer S, et al. High
381 Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-
382 CoV-2: Early Experience from California. *Gastroenterology* 2020.
- 383 [5] Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical
384 and virological characteristics of 74 cases of coronavirus-infected disease 2019
385 (COVID-19) with gastrointestinal symptoms. *Gut* 2020.
- 386 [6] Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms
387 of 95 cases with SARS-CoV-2 infection. *Gut* 2020.
- 388 [7] Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal
389 Infection of SARS-CoV-2. *Gastroenterology* 2020.
- 390 [8] Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 Expression in
391 Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. *bioRxiv*
392 2020:2020.2002.2003.931766.
- 393 [9] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Characteristics of Liver Tests in
394 COVID-19 Patients. *J Hepatol* 2020.
- 395 [10] Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern.
396 *Lancet Gastroenterol Hepatol* 2020.

Liver Chemistries in Patients with COVID-19

- 397 [11] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges.
398 Lancet Gastroenterol Hepatol 2020;5:428-430.
- 399 [12] Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of Non-ICU
400 hospitalized patients with coronavirus disease 2019 and liver injuryA Retrospective
401 study. Liver Int 2020.
- 402 [13] Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19
403 patients: a retrospective analysis of 115 cases from a single center in Wuhan city,
404 China. Liver Int 2020.
- 405 [14] Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal
406 Liver Chemistries. Am J Gastroenterol 2017;112:18-35.
- 407 [15] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The
408 PRISMA statement for reporting systematic reviews and meta-analyses of studies that
409 evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
- 410 [16] Luo D, Wan X, Liu J, Tong T. How to estimate the sample mean and standard
411 deviation from the sample size, median, extremes or quartiles? Chinese Journal of
412 Evidence-Based Medicine 2017;17:1350-1356.
- 413 [17] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med
414 2002;21:1539-1558.
- 415 [18] Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y, et al. Clinical Features of Patients
416 Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China. medRxiv
417 2020:2020.2003.2004.20030395.
- 418 [19] Cao W. Clinical features and laboratory inspection of novel coronavirus pneumonia
419 (COVID-19) in Xiangyang, Hubei. 2020:2020.2002.2023.20026963.
- 420 [20] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological
421 features of severe and moderate coronavirus disease 2019. J Clin Invest 2020.
- 422 [21] Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, et al. Epidemiological and clinical
423 features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China:

Liver Chemistries in Patients with COVID-19

- 424 a double-center observational study. medRxiv 2020:2020.2003.2003.20030353.
- 425 [22] Fu L, Fei J, Xu S, Xiang HX, Xiang Y, Tan ZX, et al. Acute liver injury and its
426 association with death risk of patients with COVID-19: a hospital-based prospective
427 case-cohort study. medRxiv 2020:2020.2004.2002.20050997.
- 428 [23] Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory
429 data determinations for patients with the severe COVID-19. J Med Virol 2020.
- 430 [24] Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, et al. Lactate dehydrogenase, a Risk
431 Factor of Severe COVID-19 Patients. 2020:2020.2003.2024.20040162.
- 432 [25] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
433 infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
- 434 [26] Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and
435 outcomes of patients undergoing surgeries during the incubation period of COVID-19
436 infection. EClinicalMedicine 2020:100331.
- 437 [27] Li D, Long YZ, Huang P, Guo WL, Wu SH, Zhou Q, et al. Clinical characteristics of
438 80 patients with COVID-19 in Zhuzhou City. Chin J Infect Control 2020;19:1-7.
- 439 [28] Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, et al. Preliminary study of
440 the relationship between novel coronavirus pneumonia and liver function damage: a
441 multicenter study. Zhonghua Gan Zang Bing Za Zhi 2020;28:148-152.
- 442 [29] Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of
443 lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2
444 infected patients. medRxiv 2020:2020.2002.2016.20023671.
- 445 [30] Liu L, Gao JY. Clinical characteristics of 51 patients discharged from hospital with
446 COVID-19 in Chongqing, China. medRxiv 2020:2020.2002.2020.20025536.
- 447 [31] Lu H, Ai J, Shen Y, Li Y, Li T, Zhou X, et al. A descriptive study of the impact of
448 diseases control and prevention on the epidemics dynamics and clinical features of
449 SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics
450 prevention. medRxiv 2020:2020.2002.2019.20025031.

Liver Chemistries in Patients with COVID-19

- 451 [32] Lu Z, He R, Jiang W, Fan T, Geng Q. Clinical characteristics and immune function
452 analysis of COVID-19. *Medical Journal of Wuhan University* 2020:1-5.
- 453 [33] Ma J, Yin J, Qian Y, Wu Y. Clinical Characteristics and Prognosis in Cancer Patients
454 with COVID-19: a Single Center's Retrospective Study. *J Infect* 2020.
- 455 [34] Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of
456 refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis* 2020.
- 457 [35] Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, et al.
458 Factors associated with hospitalization and critical illness among 4,103 patients with
459 COVID-19 disease in New York City. 2020:2020.2004.2008.20057794.
- 460 [36] Qi Wang HZ, Ligai Liu et al. . Characteristics and change patterns of liver function in
461 105 hospitalized adults patients with COVID-19 in Beijing, China. PREPRINT
462 (Version 1) available at Research Square 2020.
- 463 [37] Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, et al. Analysis of baseline
464 liver biochemical parameters in 324 cases with novel coronavirus pneumonia in
465 Shanghai area. *Zhonghua Gan Zang Bing Za Zhi* 2020;28:E005.
- 466 [38] Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte
467 ratio is associated with prognosis in patients with coronavirus disease-19. *J Med Virol*
468 2020.
- 469 [39] Shang H, Huang C, Chen Y, Zhang S, Yang P, Hong G, et al. Digestive Involvement
470 in SARS-CoV-2 Infection: A Retrospective Multi-center Study. 2020.
- 471 [40] Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment
472 of COVID-19 patients in northeast Chongqing. *J Med Virol* 2020.
- 473 [41] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
474 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
475 China. *JAMA* 2020.
- 476 [42] Wang Y, Zhou Y, Yang Z, Xia D, Geng S. Clinical Characteristics of Patients with
477 Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China.

Liver Chemistries in Patients with COVID-19

- 478 medRxiv 2020:2020.2003.2002.20029306.
- 479 [43] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With
480 Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus
481 Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020.
- 482 [44] Xiang T, Liu J, Xu F, Cheng N, Liu Y, Qian K, et al. Analysis of clinical
483 characteristics of 49 patients with coronavirus disease 2019 in Jiangxi. *Chinese
484 Journal of Respiratory and Critical Care Medicine* 2020;19:154-160.
- 485 [45] Xiong J, Jiang W, Zhou Q, Hu X, Liu C. Clinical characteristics, treatment, and
486 prognosis in 89 cases of COVID-2019. *Medical Journal of Wuhan University* 2020:1-
487 5.
- 488 [46] Xu Y, Li YR, Zeng Q, Lu ZB, Li YZ, Wu W, et al. Clinical Characteristics of SARS-
489 CoV-2 Pneumonia Compared to Controls in Chinese Han Population. medRxiv
490 2020:2020.2003.2008.20031658.
- 491 [47] Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and outcomes of
492 221 patients with COVID-19 in Wuhan, China. medRxiv
493 2020:2020.2003.2002.20030452.
- 494 [48] zhang h, wang x, fu z, luo m, zhang z, zhang k, et al. Potential Factors for Prediction
495 of Disease Severity of COVID-19 Patients. 2020:2020.2003.2020.20039818.
- 496 [49] Zhao W, Yu S, Zha X, Wang N, Pang Q, Li T, et al. Clinical characteristics and
497 durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort
498 study. medRxiv 2020:2020.2003.2013.20035436.
- 499 [50] Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of
500 161 cases of corona virus disease 2019 (COVID-19) in Changsha. *Eur Rev Med
501 Pharmacol Sci* 2020;24:3404-3410.
- 502 [51] Zheng Y, Sun L, Xu M, Pan J, Zhang Y, Fang X, et al. Clinical characteristics of 34
503 COVID-19 patients admitted to ICU in Hangzhou, China.
504 2020:2020.2004.2012.20062604.

Liver Chemistries in Patients with COVID-19

- 505 [52] Meraviglia P, Schiavini M, Castagna A, Vigano P, Bini T, Landonio S, et al.
506 Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation
507 of risk factors for liver enzyme elevation. *HIV Med* 2004;5:334-343.
- 508 [53] Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and
509 monitoring of hepatic injury. II. Recommendations for use of laboratory tests in
510 screening, diagnosis, and monitoring. *Clin Chem* 2000;46:2050-2068.
- 511 [54] Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical
512 Significance. *JPEN J Parenter Enteral Nutr* 2019;43:181-193.
- 513 [55] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of
514 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*
515 2020;368:m1091.
- 516

517 **SUPPLEMENTARY FIGURE LEGENDS**

518 Supplementary Figure 1. Association between age and disease severity

519 A, Forest plot for the association of age and disease severity. B, Funnel plot for the
520 association of age and disease severity.

521

522 Supplementary Figure 2. Funnel plot for the association of ALT/AST level and
523 disease severity

524 A, Funnel plot for the association of ALT level and disease severity. B, Funnel plot
525 for the association of AST level and disease severity.

526 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

527

528 Supplementary Figure 3. Funnel plot for the comparison between ALT and AST
529 levels stratified by disease severity

530 A, Funnel plot for the comparison of ALT and AST levels in the non-severe cases. B,
531 Funnel plot for the comparison between ALT and AST level in the severe cases.

532 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

533

534 Supplementary Figure 4. Funnel plot for the association of TBIL level and disease
535 severity

536 Abbreviations: TBIL, total bilirubin.

537

538 Supplementary Figure 5. Funnel plot for the association of ALB level/PT and disease
539 severity

540 A, Funnel plot for the association of ALB level and disease severity. B, Funnel plot
541 for the association of PT and disease severity. Abbreviations: ALB, albumin; PT,

Liver Chemistries in Patients with COVID-19

542 prothrombin time.